Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Idiopathic orbital inflammatory disease successfully treated with rituximab.

Literature DB >> 19015801

Idiopathic orbital inflammatory disease successfully treated with rituximab.

Abstract

We report a case of a 66-year-old Caucasian female with a diagnosis of idiopathic orbital inflammatory disease (OID) refractory to azathioprine therapy. The coexistence of diabetes mellitus represented a relative contraindication to chronic prednisone use. After two infusions of rituximab, a chimeric anti-CD20+ antibody, ophthalmic signs and symptoms remarkably improved. To our knowledge, this is the first case of idiopathic OID successfully treated with rituximab.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2008 PMID： 19015801 DOI： 10.1007/s10067-008-1040-8

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

8 in total

Review 1. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors: D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal: Ann Rheum Dis Date: 2007-11 Impact factor: 19.103

2. Marked bilateral parotid enlargement in metabolic syndrome: a case report and review of the literature.

Authors: Dima N Nassour; Sudhirkumar V Patel; Semaan G Kosseifi; Richard M Jordan; Alan N Peiris
Journal: Tenn Med Date: 2007-01

3. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.

Authors: R Omdal; K Wildhagen; T Hansen; R Gunnarsson; G Kristoffersen
Journal: Scand J Rheumatol Date: 2005 May-Jun Impact factor: 3.641

4. Mikulicz's disease and Mikulicz's syndrome: analysis of the original case report of 1892 in the light of current knowledge identifies a MALT lymphoma.

Authors: Stephan Ihrler; John D Harrison
Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2005-09

Review 5. Orbital inflammatory disease.

Authors: Joseph R Lutt; Lyndell L Lim; Pramit M Phal; James T Rosenbaum
Journal: Semin Arthritis Rheum Date: 2007-09-04 Impact factor: 5.532

Review 6. B cell biology and dysfunction in SLE.

Authors: Jennifer H Anolik
Journal: Bull NYU Hosp Jt Dis Date: 2007

7. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome.

Authors: Sonia J Ahn Yuen; Peter A D Rubin
Journal: Arch Ophthalmol Date: 2003-04

8. Receptor expression in orbital inflammatory syndromes and implications for targeted therapy.

Authors: V H Ho; P Chevez-Barrios; J L Jorgensen; R Z Silkiss; R Z Silkis; B Esmaeli
Journal: Tissue Antigens Date: 2007-08

8 in total

6 in total

1. Recurrent inflammatory pseudotumor of the jaw with perineural intracranial invasion demonstrating sustained response to Rituximab.

Authors: Bryan A Garcia; Sarah Tinsley; Thomas Schellenberger; George C Bobustuc
Journal: Med Oncol Date: 2011-12-08 Impact factor: 3.064

2. Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.

Authors: Eric B Suhler; Lyndell L Lim; Robert M Beardsley; Tracy R Giles; Sirichai Pasadhika; Shelly T Lee; Alexandre de Saint Sardos; Nicholas J Butler; Justine R Smith; James T Rosenbaum
Journal: JAMA Ophthalmol Date: 2014-05 Impact factor: 7.389

6. Successful corticosteroid-sparing effect of rituximab in the treatment of refractory idiopathic orbital inflammatory disease.

Authors: Emily H Shao; Andreas Karydis; Maria Gemenetzi; Simon R J Taylor
Journal: Case Rep Ophthalmol Date: 2013-11-01